Showing 1213 results
- Media Release /The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally A…
- Media Release /Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when…
- Media Release /42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1] PREVENT is…
- Media Release /The FLIGHT- FXR phase IIb study showed tropifexor, a highly potent non-bile acid FXR agonist, produces robust and dose-dependent reductions in hepatic fat and alanine aminotransferase compared to…
- Media Release /Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market Planned acquisition reinforces Sandoz…
- Media Release /Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only…
- Key Release /Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira®*[1] Statistically…
- Key Release /FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal studyAdverse events that might be expected from the pre-clinical…
- Media Release /New Cosentyx® (secukinumab) label to include 300 mg up-titration option is informed by results from the Phase III MEASURE 3 study[1] Approval provides clinicians with greater choice for their…
- Key Release /Continuing operations2 net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regionsEntresto USD 430 million (+61% cc…